Catalyst Pharm Partners Inc (NASDAQ:CPRX)

CAPS Rating: 1 out of 5

A development-stage pharmaceutical company focused on the acquisition, development and commercialization of prescription drugs for the treatment of drug addiction.

CPRX News and Commentary

Caps

How do you think CPRX will perform against the market?

Add Stock to CAPS Watchlist

All Players

61 Outperform
14 Underperform
 

All-Star Players

6 Outperform
5 Underperform
 

Wall Street

3 Outperform
0 Underperform
 

Top CPRX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.84)
Submitted July 07, 2016

Catalyst has taken some serious body blows this year and things could certainly get worse before they get better. The market hasn't been kind to wounded microchip biotech without a clearly defined upcoming catalyst. Nevertheless, I think it's more… More

zzlangerhans (99.84)
Submitted June 01, 2013

Why did a huge, successful company like Biomarin outlicense the US rights to their developmental drug Firdapse for Lambert-Eaton Syndrome to a tiny, sketchy biopharma like Catalyst? I have to admit I have no idea, but I find the recent run in… More

CPRX VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about CPRX.

Recs

0
Member Avatar Paco57 (43.38) Submitted: 12/2/2017 11:15:11 PM : Outperform Start Price: $4.46 CPRX Score: -8.60

Watch this one go!

Recs

2
Member Avatar zzlangerhans (99.84) Submitted: 7/7/2016 12:38:01 AM : Outperform Start Price: $0.74 CPRX Score: +422.70

Catalyst has taken some serious body blows this year and things could certainly get worse before they get better. The market hasn't been kind to wounded microchip biotech without a clearly defined upcoming catalyst. Nevertheless, I think it's more likely that the stock moves upward than downward from here as the company prepares to initiate a confirmatory phase III trial of Firdapse for LEMS. The prize is still within reach and management has affirmed no intention of raising cash prior to acceptance of their next NDA submission. I'm not a fan of the company and I haven't had a good record buying in this kind of situation so no real money here.

Recs

0
Member Avatar sk2129 (33.09) Submitted: 9/21/2015 11:24:22 AM : Outperform Start Price: $3.28 CPRX Score: -14.72

baker bros

Leaderboard

Find the members with the highest scoring picks in CPRX.

Score Leader

trackaegiscorp

trackaegiscorp (46.39) Score: +678.47

The Score Leader is the player with the highest score across all their picks in CPRX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Encontrado < 20 1/7/2013 Outperform 5Y $0.51 +707.92% +82.95% +624.97 0 Comment
tehpirateguy 63.60 3/15/2013 Outperform 3M $0.54 +661.90% +71.32% +590.58 0 Comment
MrTwo94 79.29 11/8/2012 Outperform 1Y $0.58 +608.83% +90.65% +518.18 0 Comment
htsigns < 20 11/8/2012 Outperform 5Y $0.59 +597.32% +91.10% +506.22 0 Comment
lfreefall < 20 11/8/2012 Outperform 5Y $0.64 +537.60% +90.07% +447.53 0 Comment
flypower 97.89 8/2/2016 Outperform 5Y $0.73 +458.90% +23.64% +435.26 0 Comment
jck444 91.33 8/3/2016 Outperform 5Y $0.74 +453.90% +23.44% +430.46 0 Comment
zzlangerhans 99.84 7/6/2016 Outperform 1Y $0.74 +451.13% +28.43% +422.70 1 Comment
bltone < 20 5/3/2013 Outperform 3Y $0.83 +392.16% +65.39% +326.77 0 Comment
dreamyy 39.13 10/27/2016 Outperform 5Y $1.07 +281.31% +24.20% +257.11 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackPiperJaff 85.03 10/5/2016 Outperform NS $1.28 +218.75% +23.72% +195.03 0 Comment
TrackMaximGroup 62.05 9/24/2013 Outperform NS $2.96 +37.84% +56.86% -19.03 0 Comment
trackaegiscorp 46.39 4/18/2013 Outperform NS $0.48 +750.00% +71.53% +678.47 0 Comment
TrackZacks < 20 9/22/2010 Outperform 3M $1.16 -62.50% +21.81% -84.31 11/9/2012 @ $0.44 1 Comment

Featured Broker Partners